Role of immune cells in AllergoOncology
This special issue belongs to
|Research & Reviews: Journal of Oncology and Hematology
Deadline for Manuscript Submission
|March 31st, 2023
Deadline for Publication
|April 15, 2023
Special Issue Description
Immune cells and immune proteins are an essential part in have reactions to microbes, allergens, and malignant growth. Figuring out the crosstalk between hypersensitive reaction and malignant growth, immune surveillance, immunomodulation, and the role of immunoglobulin E (IgE)- intervened works and assists with creating novel remedial systems. Sensitivity and oncology show two inverse situations: while resistant resilience is wanted in sensitivity, it is hindering in disease. Invigorated immune cells, as traditionally activated macrophages 'M1,' enacted dendritic cells (DCs), IL-33 and amphiregulin, inborn lymphoid cells (ILC2), NK cells, Th1, follicular T partner cells (TFH), IFN-Υ delivering T CD8+ and B lymphocytes inhibitory affect tumorigenesis and growing movement.
While tolerogenic safe cells like on the other hand activated macrophages 'M2' (M2a, M2b, and M2c), tolerogenic DCs, ILC3, T administrative, and B administrative lymphocytes, hindering unfavorably susceptible sharpening and reaction, seem to incline toward carcinogenesis. The ''immune balance'' is a fragile immune system that an insusceptible framework uses to keep up with homeostasis. Resistant resilience in sensitivity and malignant growth could address a substantial key to fostering new enemies of disease treatments.
While allergen immunotherapy (AIT) may restore resilience including Tregs, IL-10, and TGFβ, and class changing to mitigating IgG4 and IgA; in disease, safe concealment, and improvement of steady immunoregulatory reaction favor malignant growth movement. Designated spot inhibitors are skilled to break safe resistance and they have exhibited efficacies in some malignant growth types. Hostile to CTLA4 (anti cytotoxic T-lymphocytes-associated protein 4) ipilimumab and against PD1 (anti-programmed cell death protein 1) nivolumab and pembrolizumab are supported for the treatment of cutting-edge melanoma.
* Immune Cells
* Immune Proteins
* Hypersensitive reaction
* Malignanat Macrophages
Manuscript Submission information
Manuscripts should be submitted online by registering and logging in to this link. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed.
Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent on email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.